Literature DB >> 12692065

New developments in the treatment of hepatitis C.

S J Rossi1, T L Wright.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12692065      PMCID: PMC1773623          DOI: 10.1136/gut.52.5.756

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  7 in total

1.  Peginterferon alfa-2a in patients with chronic hepatitis C.

Authors:  S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

2.  A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Authors:  K L Lindsay; C Trepo; T Heintges; M L Shiffman; S C Gordon; J C Hoefs; E R Schiff; Z D Goodman; M Laughlin; R Yao; J K Albrecht
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

3.  Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Authors:  P Glue; J W Fang; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

4.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

Authors:  E J Heathcote; M L Shiffman; W G Cooksley; G M Dusheiko; S S Lee; L Balart; R Reindollar; R K Reddy; T L Wright; A Lin; J Hoffman; J De Pamphilis
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

Review 5.  Advances in hepatitis C: what is coming in the next 5 years?

Authors:  Stephen A Locarnini; Angeline Bartholomeusz
Journal:  J Gastroenterol Hepatol       Date:  2002-04       Impact factor: 4.029

Review 6.  Pegylation: a novel process for modifying pharmacokinetics.

Authors:  J M Harris; N E Martin; M Modi
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

  7 in total
  2 in total

1.  Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue.

Authors:  Donald E Bailey; Julie Barroso; Andrew J Muir; Richard Sloane; Jacqui Richmond; John McHutchison; Keyur Patel; Lawrence Landerman; Merle H Mishel
Journal:  Res Nurs Health       Date:  2010-10       Impact factor: 2.228

2.  Improving cyclodextrin complexation of a new antihepatitis drug with glacial acetic acid.

Authors:  Jennifer L H Johnson; Yan He; Akash Jain; Samuel H Yalkowsky
Journal:  AAPS PharmSciTech       Date:  2017-03-08       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.